Avoro Capital Advisors LLC
Institutional investor · Portfolio as of Q4 2019
Top Holdings31 positions
IMMUNOMEDICS INC | 24.5M | $518.4M | 15.2% | — | — | 4 qtrssince 2019-Q1 | Increased 72 |
Mirati Therapeutics Inc | 3.9M | $496.1M | 14.6% | — | — | 4 qtrssince 2019-Q1 | Increased 63 |
ASCENDIS PHARMA A/S | 1.9M | $259.5M | 7.6% | $117.47 | +15.75% | 4 qtrssince 2019-Q1 | Decreased 0 |
Iovance Biotherapeutics Inc | 8.8M | $244.3M | 7.2% | $9.82 | +180.97% | 4 qtrssince 2019-Q1 | Decreased 0 |
Sarepta Therapeutics Inc | 1.8M | $227.1M | 6.7% | $116.47 | +10.57% | 4 qtrssince 2019-Q1 | Increased 64 |
CONSTELLATION PHARMCETICLS I | 3.7M | $172M | 5.0% | — | — | 1 qtr | New 95 |
BioMarin Pharmaceutical Inc | 2M | $169.1M | 5.0% | $84.82 | -0.27% | 4 qtrssince 2019-Q1 | Decreased 0 |
ARGENX SE-ADR | 936,500 | $150.3M | 4.4% | $128.71 | +24.72% | 4 qtrssince 2019-Q1 | Increased 63 |
Horizon Pharma Plc | 4M | $144.8M | 4.3% | — | — | 3 qtrssince 2019-Q2 | Unchanged 0 |
UNIQURE NV | 1.7M | $121.8M | 3.6% | $64.73 | +10.71% | 2 qtrssince 2019-Q3 | Increased 90 |
KARYOPHARM THERAPEUTICS INC | 5.9M | $113.1M | 3.3% | — | — | — | Decreased 0 |
MYOKARDIA INC | 1.5M | $112.2M | 3.3% | — | — | 4 qtrssince 2019-Q1 | Decreased 0 |
AMICUS THERAPEUTICS INC | 11.2M | $109.1M | 3.2% | $12.97 | -26.53% | 4 qtrssince 2019-Q1 | Increased 56 |
Zogenix Inc | 2M | $104.3M | 3.1% | — | — | 4 qtrssince 2019-Q1 | Increased 60 |
Athenex Inc | 5.3M | $80.3M | 2.4% | — | — | 3 qtrssince 2019-Q2 | Decreased 0 |
Adverum Biotechnologies Inc | 5.3M | $60.5M | 1.8% | — | — | — | Increased 57 |
TRICIDA INC | 1.6M | $58.9M | 1.7% | — | — | 4 qtrssince 2019-Q1 | Decreased 0 |
AMARIN CORP PLC | 1.9M | $40.7M | 1.2% | — | — | — | Decreased 0 |
Madrigal Pharmaceuticals Inc | 349,000 | $31.8M | 0.9% | $122.42 | -25.58% | 4 qtrssince 2019-Q1 | Decreased 0 |
XENON PHARMACEUTICALS INC | 2.4M | $31.5M | 0.9% | $10.16 | +29.92% | 4 qtrssince 2019-Q1 | Unchanged 0 |
Avoro Capital Advisors LLC manages $3.4B across 31 positions as of Q4 2019. Top holdings: IMMU (15.2%), MRTX (14.6%), ASND (7.6%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 2.5/5.0.
Active quarter - 6 new positions, 10 exits, 9 increased. Top move: CNST (NEW, conviction 95). Portfolio: $3.4B across 31 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR